
November 15, 2017 - By Nellie Frank
The stock of AstraZeneca plc (ADR) (AZN) shows a multiple tops pattern with $35.58 target or 7.00 % above today’s $33.25 share price. The 8 months chart pattern indicates low risk for the $83.16 billion company. It was reported on Nov, 15 by Finviz.com. If the $35.58 price target is reached, the company will be worth $5.82 billion more.
Multiple tops are chart patterns with decent performance in a bull market. The failure rate is higher but the average decline is reasonable. Back-tests of such patterns show that the break even failure rate is 10%, the average rise: 19%, the throwback rate: 61% and the percentage of stocks meeting their price targets: 40%. The stock increased 1.00% or $0.33 during the last trading session, reaching $33.25. About 14,100 shares traded. AstraZeneca plc (ADR) (NYSE:AZN) has risen 19.45% since November 15, 2016 and is uptrending. It has outperformed by 2.75% the S&P500.Investors wait AstraZeneca plc (ADR) (NYSE:AZN) to report on February, 1. its quarterly earnings Wall Street analysts expect $0.47 earnings per share, down $0.74 or 61.16 % from last year’s $1.21 same quarter earnings. This translates into $1.18 billion profit for AZN giving the stock a 17.69 P/E. This is assuming the current $0.47 EPS is accurate. AstraZeneca plc (ADR)’s Wall Street analysts see -58.04 % negative EPS growth, taking into account the $1.12 EPS reproted in the previous quarter, Among 24 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 14 have Buy rating, 0 Sell and 10 Hold. Therefore 58% are positive. AstraZeneca plc (ADR) has $50 highest and $32 lowest target. $38.14’s average target is 14.71% above currents $33.25 stock price. AstraZeneca plc (ADR) had 39 analyst reports since July 31, 2015 according to SRatingsIntel. On Monday, October 16 the stock rating was maintained by Cowen & Co with “Hold”. On Friday, December 9 the stock rating was upgraded by Leerink Swann to “Outperform”. Argus Research upgraded AstraZeneca plc (ADR) (NYSE:AZN) rating on Monday, August 29. Argus Research has “Buy” rating and $38 target. The firm has “Buy” rating given on Monday, September 12 by Jefferies. Liberum Capital upgraded the stock to “Buy” rating in Friday, November 25 report. The stock of AstraZeneca plc (ADR) (NYSE:AZN) earned “Buy” rating by Piper Jaffray on Wednesday, August 9. Nordea downgraded AstraZeneca plc (ADR) (NYSE:AZN) on Monday, November 2 to “Hold” rating. The firm has “Market Perform” rating given on Monday, October 23 by Leerink Swann. The rating was upgraded by Bryan Garnier & Cie on Friday, September 18 to “Buy”. On Monday, May 2 the stock rating was maintained by Leerink Swann with “Market Perform”.More recent AstraZeneca plc (ADR) (NYSE:AZN) news were published by: Investorplace.com which released: “AstraZeneca plc (ADR) (AZN) Stock Tanks on Lung Cancer Drug Disappointment” on July 27, 2017. Also Investorplace.com published the news titled: “AstraZeneca plc (ADR) (AZN) Shares Soar on Lung Cancer Drug Success” on May 12, 2017. Investorplace.com‘s news article titled: “Why AstraZeneca plc (ADR) (AZN), Advanced Micro Devices, Inc. (AMD) and Spirit …” with publication date: July 27, 2017 was also an interesting one.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



(adsbygoogle = window.adsbygoogle || []).push({});
TRADE IDEAS REVIEW – IS THIS THE BEST STOCK SCANNER?

Trade Ideas is arguably one of the top scanning tools available on the market right

Trade Ideas Pro helps traders find the best setups in the market right NOW

Scottrade and E*TRADE license Trade Ideas proprietary technology for their premium trading platforms. We have fully automated trading available through Lightspeed and Interactive Brokers.Trade Ideas is the BEST Tool for Scanning. I would be LOST without Trade ideas. Ross Cameron – Warrior Trading